MSB 2.03% $1.45 mesoblast limited

banter and General Discussion, page-9965

  1. 2,978 Posts.
    lightbulb Created with Sketch. 2116
    No it is not the correct interpretation.

    Company guidance was as below- no time frame- they have now , as per last presentation, said second half of the year.

    Mesoblast intends to request a pre-BLA meeting with FDA to discuss data presentation, timing and
    FDA expectations for an accelerated approval filing in ischemic HFrEF patients with end-stage heart
    failure.


    Come back July 1


    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.